Joelle Wolf

University of Portland

Papers

1

Total Citations

2

H-Index

1

About

Dr. Joelle Wolf is a pioneering researcher in pediatric oncology, with a focused expertise in rare and high-risk subtypes of acute lymphoblastic leukemia (ALL). Her major contributions center on identifying targeted therapeutic vulnerabilities in genetically defined leukemias, particularly those with dismal prognoses. In her seminal 2018 work, Wolf demonstrated significant in vivo sensitivity to Aurora kinase inhibition in TCF3-HLF rearranged ALL—a rare, aggressive subtype with few treatment options. This study provided a critical preclinical foundation for developing targeted therapies against this fusion-driven leukemia, which is characterized by distinct gene expression profiles and drug sensitivities. Although her most-cited paper has garnered 2 citations to date, its impact is substantial within the niche field of rare leukemia subtypes, where each advance represents a lifeline for affected patients. Wolf’s research bridges molecular genetics and pharmacology, offering hope for translating laboratory insights into clinical trials. Her work underscores the importance of precision medicine in pediatric cancers, and she continues to be a vital voice in advancing treatments for the most challenging forms of childhood leukemia.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia
2 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: University of Portland

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago